Xintela AB (XINT) Stock Overview

Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company develops products based on XINMARK, a patented technology platform; XSTEM, a stem cell platform for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; EQSTEM for the joint disease treatment in horses; CANISTEM for stem cell treatment in dogs; and XACT, an analytical test for cartilage cells. It is also involved in the development of TARG9 and TARG10, therapeutic antibodies targeting integrin aiopi for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. The company's trademarks also include XINTELA and TARGINTA. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.